RBC Capital analyst Brian Abrahams raised his price target for Sarepta to $220 from $180 and maintained an Outperform rating, telling investors in a research note that he sees Sarepta as the "clear leader" in the Duchenne Muscular Dystrophy space. The analyst says he looks for initiation of the company's confirmatory study with commercial supply as the next catalyst for this program and expect continued share upside as investors should begin to better appreciate its other gene therapy assets in development. While manufacturing and ability to show functional benefits in a more inclusive study remain risks, Abrahams says he now sees a reasonable likelihood Sarepta can generate $4B per year with microdystrophin.